Yıl: 2024 Cilt: 13 Sayı: 1 Sayfa Aralığı: 61 - 66 Metin Dili: İngilizce DOI: 10.5455/medscience.2023.09.193 İndeks Tarihi: 03-07-2024

Hidden enemy of pulmonary arteries: COVID-19

Öz:
It has been reported that COVID-19 may cause severe endothelial damage. Pulmonary Artery Stiffness (PAS) is a strong predictor of right ventricular function. PAS can reveal important information about the endothelial functions of the pulmonary bed. In this study, we aimed to elucidate the possible effect of COVID-19 on PAS. The study was performed by measuring PAS values with transthoracic echocardiography in 130 patients, 60 of whom had COVID-19 and 70 were controls. COVID-19 patients with positive polymerase chain reaction (PCR) test results were included in the study 3-6 months after their positivity. When the Maximal frequency shift (MFS) (Hz) results were examined, no significant difference was observed between the patient and control groups (2764±279.24 and 2664.8±673.91 p=0.340, respectively). There was a significant difference between the patient and control groups in favor of the patient group in pulmonary acceleration time (PAT) (msec) results (93.18±14.99 and 126.1±17.58, respectively, p<0.001). There was a significant difference between the patient and control groups in favor of the patient group in PAS (Hz/msec) results (30.28±5.07 and 21.57±7.04, respectively, p<0.001). It is possible that COVID-19 may have adverse effects on the pulmonary artery wall and bed. As a result of endothelial damage due to COVID-19, an increase in PAS values can be observed.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
0
0
0
  • 1. Gattinoni L, Gattarello S, Steinberg I, et al. COVID-19 pneumonia: pathophysiology and management. Eur Respir Rev. 2021;30:210138.
  • 2. Wichmann D, Sperhake J-P, Lutgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. 2020;173:268-77.
  • 3. Zhao L, Wang X, Xiong Y, et al. Correlation of autopsy pathological findings and imaging features from 9 fatal cases of COVID-19 pneumonia. Medicine. 2021;100:e25232.
  • 4. Touman A, Kahyat M, Bulkhi A, et al. Post COVID-19 chronic parenchymal lung changes. Cureus. 2022;14:e25197.
  • 5. Fabbri L, Moss S, Khan FA,et al. Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax. 2023;78:191-201.
  • 6. Gupta A, Sharifov OF, Lloyd SG, et al. Novel noninvasive assessment of pulmonary arterial stiffness using velocity transfer function. J Am Heart Assoc. 2018;7:e009459.
  • 7. Wibmer T, Rüdiger S, Scharnbeck D, et al. Pulmonary pulse transit time: a novel echocardiographic indicator of hemodynamic and vascular alterations in pulmonary hypertension and pulmonary fibrosis. Echocardiography. 2015;32:904-11.
  • 8. Görgülü S, Eren M, Yildirim A, et al. A new echocardiographic approach in assessing pulmonary vascular bed in patients with congenital heart disease: pulmonary artery stiffness. Anadolu Kardiyol Derg. 2003;3:92-7.
  • 9. Wang Z, Chesler NC. Pulmonary vascular wall stiffness: an im- portant contributor to the increased right ventricular afterload with pulmonary hypertension. Pulm Circ. 2011;1:212-23.
  • 10. Rochette L, Zeller M, Cottin Y, Vergely C. GDF15: an emerging modulator of immunity and a strategy in COVID-19 in association with iron metabolism. Trends Endocrinol Metab. 2021;32:875-89.
  • 11. Peled N, Shitrit D, Fox BD, et al. Endothelial dysfunction, arterial stiffness, and heart failure, peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol. 2009;36:970-5.
  • 12. Fortini A, Torrigiani A, Sbaragli S, et al. COVID-19: persistence of symptoms and lung alterations after 3-6 months from hospital discharge. Infection. 2021;49:1007-15.
  • 13. Özcan S, İnce O, Güner A, et al. Long-term clinical consequences of patients hospitalized for COVID-19 infection. Anatol J Cardiol. 2022;26:305-15.
  • 14. Myhre PL, Heck SL, Skranes JB, et al. Cardiac pathology 6 months after hospitalization for COVID-19 and association with the acute disease severity. Am Heart J. 2021;242:61-70
  • 15. Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108.
  • 16. Sardu C, Gambardella J, Morelli MB, et al. Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. J Clin Med. 2020;9:1417.
  • 17. Buja LM, Wolf DA, Zhao B, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48:107233.
  • 18. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120-8.
  • 19. Zhou B, Zhao W, Feng R, et al. The pathological autopsy of coronavirus disease 2019 (COVID-2019) in China: a review. Pathogens Dis. 2020;78:026.
  • 20. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog. 2020;16:e1008536.
  • 21. Ekholm M, Kahan T. The impact of the renin-angiotensin-aldosterone system on inflammation, coagulation, and atherothrombotic complications, and to aggravated COVID-19. Front Pharmacol. 2021;12:640185.
  • 22. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389-91.
  • 23. Lammers S, Scott D, Hunter K, et al. Mechanics and function of the pulmonary vasculature: implications for pulmonary vascular disease and right ventricular function. Compr Physiol. 2012;2:295-319.
  • 24. Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004;43:25S-32S.
  • 25. Duman D, Masatlioğlu S, Demirtunç R, Karadağ B. Increased pulmonary artery stiffness and its relation to right ventricular function in patients with systemic lupus erythematosus. Turk Kardiyol Dern Ars. 2008;36:82-9.
  • 26. Cerik IB, Meric M, Gulel O, et al. Echocardiographic assessment of pulmonary arterial stiffness in human immunodeficiency virus-infected patients. Echocardiography. 2019;36:1123-31.
  • 27. Agoston-Coldea L, Lupu S, Mocan T. Pulmonary artery stiffness by cardiac magnetic resonance imaging predicts major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. Sci Rep. 2018;8:144-7.
  • 28. Sanz J, Kariisa M, Dellegrottaglie S, et al. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance. JACC Cardiovasc Imaging. 2009;2:286-95.
  • 29. Tudoran C, Tudoran M, Lazureanu VE, et al. Evidence of pulmonary hypertension after SARS-CoV-2 infection in subjects without previous significant cardiovascular pathology. J Clin Med. 2021;10:199.
  • 30. Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106:1324-31.
APA Duygu A, KÜÇÜK U (2024). Hidden enemy of pulmonary arteries: COVID-19. , 61 - 66. 10.5455/medscience.2023.09.193
Chicago Duygu Ali,KÜÇÜK UĞUR Hidden enemy of pulmonary arteries: COVID-19. (2024): 61 - 66. 10.5455/medscience.2023.09.193
MLA Duygu Ali,KÜÇÜK UĞUR Hidden enemy of pulmonary arteries: COVID-19. , 2024, ss.61 - 66. 10.5455/medscience.2023.09.193
AMA Duygu A,KÜÇÜK U Hidden enemy of pulmonary arteries: COVID-19. . 2024; 61 - 66. 10.5455/medscience.2023.09.193
Vancouver Duygu A,KÜÇÜK U Hidden enemy of pulmonary arteries: COVID-19. . 2024; 61 - 66. 10.5455/medscience.2023.09.193
IEEE Duygu A,KÜÇÜK U "Hidden enemy of pulmonary arteries: COVID-19." , ss.61 - 66, 2024. 10.5455/medscience.2023.09.193
ISNAD Duygu, Ali - KÜÇÜK, UĞUR. "Hidden enemy of pulmonary arteries: COVID-19". (2024), 61-66. https://doi.org/10.5455/medscience.2023.09.193
APA Duygu A, KÜÇÜK U (2024). Hidden enemy of pulmonary arteries: COVID-19. Medicine Science, 13(1), 61 - 66. 10.5455/medscience.2023.09.193
Chicago Duygu Ali,KÜÇÜK UĞUR Hidden enemy of pulmonary arteries: COVID-19. Medicine Science 13, no.1 (2024): 61 - 66. 10.5455/medscience.2023.09.193
MLA Duygu Ali,KÜÇÜK UĞUR Hidden enemy of pulmonary arteries: COVID-19. Medicine Science, vol.13, no.1, 2024, ss.61 - 66. 10.5455/medscience.2023.09.193
AMA Duygu A,KÜÇÜK U Hidden enemy of pulmonary arteries: COVID-19. Medicine Science. 2024; 13(1): 61 - 66. 10.5455/medscience.2023.09.193
Vancouver Duygu A,KÜÇÜK U Hidden enemy of pulmonary arteries: COVID-19. Medicine Science. 2024; 13(1): 61 - 66. 10.5455/medscience.2023.09.193
IEEE Duygu A,KÜÇÜK U "Hidden enemy of pulmonary arteries: COVID-19." Medicine Science, 13, ss.61 - 66, 2024. 10.5455/medscience.2023.09.193
ISNAD Duygu, Ali - KÜÇÜK, UĞUR. "Hidden enemy of pulmonary arteries: COVID-19". Medicine Science 13/1 (2024), 61-66. https://doi.org/10.5455/medscience.2023.09.193